The aim of this study was to investigate the clinical characteristics and the risk factors associated with antituberculosis (anti-TB) drug-induced liver injury (DILI).
Background
Tuberculosis (TB) is a chronic infection of global health concern due to the burden of high incidence, medical expenses, drug resistance, and coinfections [1] . China reports the second highest incidence of TB reported worldwide. with up to 1 300 000 new cases reported each year [2] .
A combination of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol is the commonly recommended treatment regimen for TB. However, drug-induced liver injury (DILI) is a major adverse event of anti-TB treatment, leading to nonadherence, treatment failure, or development of drug resistance. Globally, anti-TB DILI is reported in 2% to 28% [3] of patients according to various definitions, study populations, and treatment regimens, with China reporting an incidence rate of 2.55% [4] .
The clinical features of anti-TB DILI can vary from mild asymptomatic elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to acute hepatitis or even liver failure. Although many studies have revealed the clinical features and outcomes of anti-TB DILI [3] , the results have failed to explain the relationships between clinical and biochemical characteristics and outcomes of anti-TB DILI. The aim of the present retrospective study was to assess the clinical features, biochemical characteristics, and the outcomes of anti-TB DILI by following up these patients for 24 weeks.
Material and Methods

Study design and population
This was a single-center, retrospective cohort study conducted at the Liver Disease Center of Beijing Ditan Hospital. We enrolled 140 TB patients who were hospitalized with a diagnosis of drug-induced liver injury during anti-tubercular treatment between January 2009 and December 2015.
Patients ages 15-80 years were included in the study if they had: (1) normal liver function prior to the initiation of antitubercular treatment; (2) clinical symptoms of anti-tuberculosis drug-induced hepatotoxicity including fatigue, gastrointestinal disturbances, jaundice, or allergic manifestations; (3) abnormal liver function test; and (4) Roussel Uclaf Causality Assessment Method (RUCAM) simplified version [5] score of ³6.
Exclusion criteria were: liver abnormalities prior to anti-tubercular treatment, including viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease, Wilson's disease, autoimmune liver disease, unexplained liver function abnormalities; malnourished patients; patients with chronic diseases such as HIV infection, severe cardiovascular and/or cerebrovascular diseases, chronic renal insufficiency; and patients who could not participate in follow-up on time.
The study protocol was approved by the Institutional Review Board (IRB) of Beijing Ditan Hospital and conformed to the standards of the Declaration of Helsinki and its subsequent revisions.
Clinical classification of drug-induced liver injury
Based on the modified criteria for DILI [3] and the criteria established by the Chinese Medical Association, we categorized the patients into 3 categories [6]:
(1) hepatocellular injury, ALT ³3×ULN and ALT/ALP ³5; (2) cholestatic injury, ALP ³2×ULN and ALT/ALP £2; (3) hepatocellular-cholestatic mixed injury, ALT ³3×ULN, ALP ³2×ULN and 2< ALT/ALP <5.
Classification criteria for the severity of drug-induced liver injury
Based on the different expert opinions put forward, we classified the severity of acute DILI into 5 grades [6] : 
Baseline examinations
Baseline evaluations included total physical examination and recording the vital signs, laboratory tests (complete blood cell count, urine examination, fecal occult blood, PTA, liver function tests, kidney function tests, blood lipids, blood sugar, autoantibodies and hepatitis virus panel), and abdominal Doppler examination (liver, gallbladder, Spleen, ascites, portal blood flow).
Treatment
The patients were advised to stop taking all anti-TB drugs immediately and were recommended to have a light diet along with ample bed rest. According to patients' individual conditions, they were treated with hepatoprotective agents; emergency liver transplantation was considered for patients with ALF/SALF.
Follow-up
Patients were followed up closely by a chest physician and a hepatologist weekly for the first 2 weeks and then were followed up at 4, 12, and 24 weeks. At each visit, the patients underwent a complete physical examination, including recording of the vital signs and laboratory tests (blood routine, PTA, liver and kidney function tests). At 24 weeks, the abdominal Doppler scan was repeated.
Statistical analysis
Statistical analysis was performed using SPSS 17.0. Quantitative data are expressed as mean±standard deviation. Comparison between groups was performed by t test or variance test. Nonnormally distributed quantitative data were analyzed by nonparametric rank sum test, Wilcoxon test, or Kruskal-Wallis test; qualitative data are represented using frequency or rate. The differences between groups were analyzed by chi-square 
Results
Baseline characteristics
Among the 140 patients diagnosed with anti-TB DILI, 82 (58.6%) were males and 58 (41.4%) were females, with a mean age of 41 years. In our study, 104 patients had pulmonary TB, while extra-pulmonary TB involved the pleura in 25 patients, lymph nodes in 9 patients, and meninges in 1 patient. Concomitant medications included: 15 patients on long-term antihypertensive drugs, 12 patients on long-term hypoglycemic drugs, and 2 patients on allopurinol for hyperuricemia. The time interval from onset of anti-tuberculosis therapy and the detection of hepatotoxicity ranged from 7 to 90 days, and the average time was 24 days.
Based on the severity of liver injury, patients were categorized into 2 groups: Group A consisted of 111 patients with grades 1-3 DILI and Group B consisted of 29 patients with grades 4-5 DILI. The baseline characteristics of both groups are demonstrated in Table 1 The proportion of patients who had re-challenge anti-TB therapy in group B was significantly higher than in group A (41.4% vs. 10.8, P<0.001).
Clinical features in study population
The clinical manifestations of anti-TB DILI reported in our study population included loss of appetite (n=104), fatigue (n=94), brown urine (n=90), fever (n=49), and rash (n=22). Clinical manifestations of fever, change in urine color, and loss of appetite was significantly more frequent in patients with grades 4-5 DILI in comparison to those with grades 1-3 DILI (Table 1) . According to the clinical classification, 96 patients were diagnosed with hepatocellular type, while 24 patients had cholestasis type, and 20 patients reportedly had mixed-type injury.
Laboratory diagnosis
The detailed laboratory analysis is shown in 
Outcome of treatment
All the patients in group A (grades 1-3) and 19 patients in group B (grades 4-5) recovered and were discharged from the hospital, while 10 patients in group B died because of liver disease.
Clinical features and laboratory tests in grades 4-5 DILI
Based on the treatment outcomes, we categorized group B patients into 2 sub-groups: a fatality group and an improvement group. The baseline characteristics, clinical features, and laboratory analysis of these groups are detailed in Tables 3 and 4 
Discussion
In our study, we analyzed the incidence, clinical manifestations, biochemical characteristics, and outcomes based on the different grades of anti-DILI.
The average time elapsed from the initiation of anti-TB treatment to developing DILI was about 24 days, with longer onset time in patients with grade 1-3 in comparison to those with grade 4-5. The onset time reported in our study was shorter than that reported by et al. [7] , who reported a median evolving time of 30 days, and was shorter than that found by Kumar et al. [8] , who reported a median time of 28 days.
The clinical manifestations of anti-tuberculosis drug-induced liver injury are diverse and non-specific and can vary from an asymptomatic liver dysfunction to severe acute hepatitis, or even acute liver failure. The mechanism by which drug-induced hepatotoxicity occurs mainly involves hypersensitivity reactions clinically manifesting as fever, rash, or eosinophilia. In our study, the most common clinical manifestations were fever, rash, fatigue, loss of appetite, and dark brown urine. Although some patients present with clinical symptoms, about 20% of patients presents with asymptomatic transaminase elevation with standard anti-TB drug therapy [9, 10] . In the course of treatment, the drug that likely caused the liver damage should be stopped and the use of prescribed liver-protecting drugs should be minimized to avoid exacerbations caused by recurrence of allergic reactions [11] . Liver injury can be fatal if diagnosis and management are not initiated immediately. Hence, it is advisable to routinely monitor liver function in patients receiving anti-TB drugs.
In the current cohort of anti-TB DILI patients, hepatocyte injury was more common compared to cholestasis and mixedtype liver injury. Liver injury is more severe in hepatocellular type, while patients with cholestatic/mixed type are more likely to develop chronic disease [12, 13] . Studies have found that hepatocellular injury is more common in young females, while the cholestatic type of DILI is more common among the elderly, but it remains unclear why there is an association between age and DILI phenotypes [14] .
According to the literature, there are many factors affecting the severity of DILI, including advanced age, female sex, alcohol consumption, and malnutrition [15] [16] [17] [18] [19] . In the present study we found no significant difference in age of patients diagnosed with grades 1-3 compared to those with grades 4-5 DILI.
We also observed that patients with grades 4-5 who died were younger in comparison to those who survived. However, Sharma et al., in India, reported deaths at an average age of 34.8±16.8 years whereas that of the survivors was 28.8±12.9 years [8] . There are few studies that have reported no associations between age and gender with DILI. It has been reported that women are at increased risk of developing hepatotoxicity when receiving anti-tuberculosis treatment. In the present study, the proportion of women with grades 4-5 liver injury was higher than that of men, suggesting that women receiving anti-tuberculosis drugs may be more prone to severe liver damage or even liver failure. Ichai et al. [20] and Kumar et al. [21] conducted studies in France and India, respectively, and both reported anti-TB drug-associated liver failure in about 70% of female patients.
Other risk factors associated with anti-TB DILI include alcoholism and viral hepatitis. Anand et al. reported that patients with hepatitis B virus infection had significantly higher incidence of anti-TB DILI than those without infection (37.5% vs. 10.2%, p<0.01) [21] . The patients enrolled in our study had normal liver function before anti-tuberculosis treatment, and the results suggested that the severity of liver injury was not related to the presence of primary liver disease.
Most cases of anti-TB DILI are associated with multidrug combination therapy. In the present study, more patients who were treated by the combination of rifampicin+isoniazid+pyrazina mide were diagnosed with severe liver injury in comparison to those receiving other anti-tuberculosis treatment regimens. Earlier preclinical and clinical studies have demonstrated the synergistic effect of isoniazid and rifampicin on liver damage, and they concluded that the incidence of liver damage is significantly higher in combination doses [22] . A study that included 3007 patients with tuberculosis found that the incidence of DILI in patients treated with rifampicin+isoniazid was 0.8%, and this increased to 2.8% after the addition of pyrazinamide, suggesting that rifampicin+isoniazid+pyrazinamide triple therapy can increase the risk of DILI and affect the severity of liver damage [23] .
Although some drugs cause mild liver injury during the first exposure, drug re-challenge can cause severe damage leading to fatal reactions [24] . Re-challenge can help identify risk factors associated with drug-induced liver injury and aids in timely diagnosis. However, due to the high risk associated with re-challenge, it is generally not recommended unless the patient has no other available alternative regimen. In our study, the degree of liver injury was more severe in the re-challenge group. Among the 24 patients who reinitiated the previous 
